Synexus supports World Diabetes day – 14 November

Synexus supports World Diabetes day – 14 November

World Diabetes Day aims to:

  • Be the platform to promote IDF advocacy efforts throughout the year.
  • Be the global driver to promote the importance of taking coordinated and concerted actions to
    confront diabetes as a critical global health issue.

WDD is the world’s largest diabetes awareness campaign reaching a global audience of over 1 billion people in more than 160 countries. The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public and political spotlight.
The campaign is represented by a blue circle logo that was adopted in 2007 after the passage of the UN Resolution on diabetes.
The blue circle is the global symbol for diabetes awareness. It signifies the unity of the global diabetes community in response to the diabetes epidemic.

The theme of World Diabetes Day 2017 is Women and diabetes – our right to a healthy future

The campaign will promote the importance of affordable and equitable access for all women at risk for or living with diabetes to the essential diabetes medicines and technologies, self-management education and information they require to achieve optimal diabetes outcomes and strengthen their capacity to prevent type 2 diabetes.

Gender roles and power dynamics influence vulnerability to diabetes, affect access to health services and health seeking behavior for women, and amplify the impact of diabetes on women. Diabetes is the ninth leading cause of death in women globally, causing 2.1 million deaths each year.

As a result of socioeconomic conditions, girls and women with diabetes experience barriers in accessing cost-effective diabetes prevention, early detection, diagnosis, treatment and care, particularly in developing countries.

Information from the International Diabetes Federation. Learn more about diabetes here

To learn more about the Synexus clinical trials for  people with diabetes. Go to our page

All clinical studies are approved by the Medicines Control Council and the relevant ethics committee.

 

 

Your feedback is vital to the success of our research. Please fill in the form fields below.